Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Adr3.4

Adrafinil (Olmifon) – Forschung

Überwiegend Mechanismus / Beobachtung

6 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Adrafinil (Olmifon) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen Studien, veröffentlicht 2000–2020.

Basierend auf 6 Studien

Konfidenz

Geringe Konfidenz

Nach Outcome

Cognition & vigilance
Überwiegend Mechanismus / Beobachtung4 Studien
Wakefulness & fatigueFördert Wachheit, Vigilanz und Wachzustand über seinen Modafinil-Metaboliten; historisch vermarktet bei reduzierter Vigilanz und Aufmerksamkeit bei älteren Patienten · 1-2 Stunden nach einer Dosis
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie

Ältere Forschungsbasis

Neueste Studie von 2020

200020102020

1Übersicht2018

Adrafinil, a new molecule identified by a French drug company, L. Lafon Ltd, in 1974 … the kinetics of adrafinil led to the identification of an active metabolite, modafinil.

Billiard, Broughton · Sleep medicine (2018)

Historical review tracing adrafinil (identified by Lafon in 1974) and the discovery of its active metabolite, modafinil
Michel Jouvet prescribed adrafinil to narcoleptic patients as early as 1977–78 but 'without consistent results'
Modafinil was discovered through adrafinil's pharmacokinetics and went on to become the better-characterized drug

Quelle ansehen

2Übersicht2020

A review of modafinil (and of its prodrug adrafinil and its enantiomer armodafinil) pharmacokinetics, pharmacodynamics and clinical and forensic aspects.

Sousa, Dinis-Oliveira · Substance abuse (2020)

Pharmacokinetic/pharmacodynamic review that frames adrafinil explicitly as the prodrug of modafinil
Wakefulness is driven by the modafinil metabolite acting on catecholamine, orexin, and histamine arousal systems
Covers the clinical and forensic (doping) context in which adrafinil is now mostly encountered

Quelle ansehen

3Tierstudie2000

Treatment with adrafinil produced significant improvement in learning of a discrimination task in aged beagle dogs.

Milgram, Siwak, Gruet, Atkinson · Pharmacology, biochemistry, and behavior (2000)

Aged beagle dogs trained on size or intensity discrimination 2 h after 20 mg/kg adrafinil or placebo (counterbalanced crossover)
Adrafinil significantly improved acquisition of the discrimination task versus placebo
Among the cleanest direct efficacy signals for adrafinil — but it is an animal model of cognitive aging

Quelle ansehen

4Tierstudie2000

Dogs were randomly assigned to receive adrafinil … propentofylline … or nicergoline … for 33 days.

Siwak, Gruet, Woehrlé, Muggenburg, Murphey · American journal of veterinary research (2000)

Randomized comparison in 36 aged beagles: adrafinil (20 mg/kg/day) vs propentofylline vs nicergoline over 33 days
Adrafinil increased open-field locomotor and exploratory behavior in aged dogs
Supports a behavioral-activation (vigilance) effect, consistent with its wake-promoting mechanism

Quelle ansehen

5Tierstudie2003

Adrafinil disrupts performance on a delayed nonmatching-to-position task in aged beagle dogs.

Siwak, Tapp, Milgram · Pharmacology, biochemistry, and behavior (2003)

Aged beagles tested on a delayed-nonmatching-to-position (working-memory) task after 10 or 20 mg/kg adrafinil or placebo
Adrafinil DISRUPTED performance on the memory task rather than improving it
Shows the cognitive effect is not uniformly positive and may impair working memory while activating behavior

Quelle ansehen

6Fallstudie2004

We describe the first case of orofacial abnormal movements induced by adrafinil … the dyskinesias did not spontaneously recover despite adrafinil withdrawal for a 4-month period.

Thobois, Xie, Mollion, Benatru, Broussolle · Movement disorders : official journal of the Movement Disorder Society (2004)

Case report of persistent orofacial dyskinesia attributed to adrafinil
The abnormal movements did not resolve after 4 months off the drug; they improved only with tetrabenazine
Documents a real, durable neurological adverse effect in a human user

Quelle ansehen

In der Forschungsbibliothek ansehen

Adrafinil (Olmifon) – Forschung

Überwiegend Mechanismus / Beobachtung

Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions.

Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects.

Oral administration of adrafinil improves discrimination learning in aged beagle dogs.

Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs.

Adrafinil disrupts performance on a delayed nonmatching-to-position task in aged beagle dogs.

Adrafinil-induced orofacial dyskinesia.